Compare Duke Energy Corp (DUK) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Duke Energy Corp trades at $121.04 (market cap $93.28B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Duke Energy Corp is far larger — about 95.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Duke Energy Corp pays a 3.63% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 75 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| DUK | MRVI | |
|---|---|---|
Market Cap | $93.28B | $977.37M |
Volume | 4,666,371 | 2,742,564 |
Sector | Utilities | Health |
52-Week High | $133.46 | $9.00 |
52-Week Low | $113.23 | $2.83 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $185.79B | $1.08B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $118.19, up 0.42% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with consistent earnings beats, 15.78% net margin, and stable dividend payments. Revenue growth from $28.8B in 2022 to $32.2B in 2025 reflects operational strength, though rising debt levels warrant monitoring. Recent news highlights dividend declarations and data center growth opportunities.
DUK presents a balanced outlook with analyst consensus at $131.50 (43.75% buy ratings). Key opportunities include data center demand and dividend reliability, while risks involve rising Treasury yields pressuring utility stocks and increasing debt-to-asset ratio (46.17% in 2025). The stock offers value with a P/E of 17.8 and positive cash flow projections for 2026.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
